2) cardiotoxicity
心脏毒性
1.
Analysis of Cardiotoxicity of Recombinant Human Endostatin Combined with Chemotherapy;
重组人血管内皮抑素联合化疗心脏毒性的分析
2.
Protective effect of gypenosides on adriamycin induced acute cardiotoxicity in rats;
绞股蓝总皂苷对阿霉素致大鼠急性心脏毒性的保护作用
3.
Signal pathways in doxorubicin-induced cardiotoxicity;
多柔比星致心脏毒性的可能信号途径
3) Cardiotoxity
心脏毒性
1.
Eprirubincin-induced Cardiotoxity in Breast Cancer Patients by Clinical Application of the New Echocardiography Technologies;
超声新技术评价乳腺癌术后患者表阿霉素化疗心脏毒性的价值
2.
Clinical Study of Echocardiography in Assessment of Cardiotoxity in Breast Cancer Patients Treated with Anthracycline;
超声心动图评价蒽环类药对乳腺癌患者心脏毒性的临床研究
3.
Clinical Study of Myocardial Integrated Backscatter Parameters in Assessment of Cardiotoxity of Patients Treated with Anthracycline;
心肌背向散射积分参数评价蒽环类抗肿瘤药心脏毒性的临床研究
4) cardiac toxicity
心脏毒性
1.
Clinical assessment of cTnI in cardiac toxicity of cyclophosphamide pulse therapy for lupus nephritis
心肌肌钙蛋白Ⅰ对环磷酰胺冲击治疗狼疮肾炎心脏毒性评估的临床意义
2.
Monitoring L-carnitine to reduce cardiac toxicity of anthracyclines
左旋肉碱监测及防治蒽环类抗生素心脏毒性作用
3.
Conclusion:PNS at larger doses (≥150 mg·kg-1) possesses the potential of cardiac toxicity; however the accumulative effect of PNS is not obvious.
结论:大剂量(≥150mg·kg-1)三七总皂苷具有心脏毒性作用,但没有心脏蓄积作用。
5) cardiotoxicity
心脏毒性反应
1.
Observation of cardiotoxicity induced by continuous intravenous infusion of high-dose epirubicin;
表阿霉素大剂量持续静滴对心脏毒性反应的观察
6) doxorubicin-induced cardiotoxicity
阿霉素心脏毒性
1.
However,doxorubicin-induced cardiotoxicity is the mainly adverse effect in clinic.
采用单次15 mg·kg~(-1)腹腔注射阿霉素造成小鼠急性心脏毒性模型,通过测定心室内压、血清心肌酶谱、组织抗氧化酶活力及高能磷酸物质含量、组织和心肌细胞超微结构等多方面的指标,综合评价PNS抗阿霉素心脏毒性的作用。
补充资料：非心
1.邪心。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条